AUS
NZ
UK
CA
USA
IND
Highlights
- Immuron reported unaudited FY26 global sales of AUD 7.7 million, up 6% from the prior corresponding period.
- Travelan sales in Australia increased 10% during FY26, supported by marketing, retail expansion and travel demand.
- U.S. sales rose 7% in AUD terms and 13% in USD terms following multiple marketing initiatives.
- Canada recorded a sharp improvement in quarterly sales as brand awareness and retail promotions gained traction.
Immuron Limited (ASX:IMC; NASDAQ: IMRN) has closed FY26 with another year of higher sales, marking four consecutive quarters of growth compared with the prior corresponding period. The company reported unaudited global sales of AUD 7.7 million for FY26, up 6% year on year, as Travelan continued to gain traction across Australia, the United States and Canada. The latest results reflect a combination of marketing initiatives, retail expansion and growing consumer awareness, while highlighting varying regional performance across key markets.
Global Sales Continue to Build
Immuron reported FY26 global sales of AUD 7.7 million, representing a 6% increase over the prior corresponding period. Second-half FY26 sales reached AUD 3.5 million, up 7%, while fourth-quarter sales totalled AUD 2.0 million, an increase of 2%.
The company said the results marked the fourth consecutive quarter of sales growth compared with the prior year, reflecting continued demand for Travelan, its over-the-counter immune supplement designed to target pathogenic bacteria and toxins in the gastrointestinal tract.
Australia Remains the Largest Contributor
Australia remained Immuron's largest market, with FY26 sales rising 10% to AUD 5.8 million. Second-half sales increased 6% to AUD 2.5 million, while fourth-quarter sales edged 1% higher to AUD 1.6 million.
Growth was supported by increased digital and social media marketing, higher same-store sales driven by promotions and returning customers, expansion into additional stores secured during FY25, and increased travel to South East Asia. Immuron also introduced new Travelan packaging and creative material during the fourth quarter, which it expects to support future sales.
Marketing Initiatives Lift U.S. Performance
In the United States, FY26 sales increased 7% to AUD 1.8 million, while sales in U.S. dollar terms rose 13% to USD 1.2 million.
The company attributed the growth to several marketing initiatives, including improvements to the Travelan Amazon store, dedicated U.S. Facebook and Instagram pages, and expanded paid, influencer and organic social media campaigns. However, the strengthening Australian dollar reduced reported growth in AUD terms during the second half and fourth quarter.
Canada Recovery Gains Momentum
Canada remained the smallest contributor, with FY26 sales of AUD 0.2 million, down 55% on the prior corresponding period. Despite the annual decline, momentum improved throughout FY26.
Immuron highlighted that consumer promotions contributed to higher quarterly sales following the expansion into more than 1,000 retail locations secured during FY25. The company continued to build Travelan brand awareness through in-store education programs, retail promotions and social media marketing, resulting in fourth-quarter sales increasing 427% over the prior corresponding period.
Travelan Remains Central to Immuron's Business
Travelan is an orally administered passive immunotherapy developed using Immuron's proprietary platform technology based on hyper-immune bovine colostrum. The product is designed to reduce the likelihood of travellers' diarrhoea by binding to diarrhoea-causing bacteria in the gastrointestinal tract. Travelan is listed on the Australian Register for Therapeutic Goods, licensed as a natural health product in Canada, and sold as a dietary supplement in the United States.
Immuron continues to focus on developing and commercialising orally delivered targeted polyclonal antibodies for infectious diseases through its proprietary technology platform.
IMC shares traded at AUD 0.043, at the time of writing on 16 July 2026.
